BioNTech
BNTX
281 hedge funds and large institutions have $4.88B invested in BioNTech in 2023 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 92 increasing their positions, 88 reducing their positions, and 64 closing their positions.
5% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 88
0.17% more ownership
Funds ownership: 16.35% → 16.52% (+0.17%)
12% less funds holding
Funds holding: 319 → 281 (-38)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
19% less capital invested
Capital invested by funds: $6.02B → $4.88B (-$1.14B)
52% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 64
62% less call options, than puts
Call options by funds: $114M | Put options by funds: $303M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
+$131M |
| 2 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
+$75.4M |
| 3 |
Morgan Stanley
New York
|
+$70M |
| 4 |
Primecap Management
Pasadena,
California
|
+$55.1M |
| 5 |
Millennium Management
New York
|
+$47.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$99.3M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$93M |
| 3 |
Coatue Management
New York
|
-$92.9M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$57.5M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$45.5M |
BNTX Hedge Fund Activity: Q1 2023 in Review
281 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q1 2023, worth a combined $4.88B — down 19% from $6.02B a quarter earlier.
Sellers outnumbered buyers: 64 funds closed out of BNTX and 31 opened new positions — a net loss of 33 holders — while 88 trimmed existing stakes and 92 added.
The largest buyer was Envestnet Asset Management, adding an estimated $131M. The largest seller was T. Rowe Price Associates, cutting an estimated $99.3M.
- 281 institutional investors held BioNTech (BNTX) as of Q1 2023, down from 319 in Q4 2022.
- Funds reported $4.88B of BioNTech stock for Q1 2023, down 19% quarter-over-quarter.
- 31 funds opened new BioNTech positions in Q1 2023 and 64 closed out, a net change of -33 holders.
- The largest BioNTech buyer in Q1 2023 was Envestnet Asset Management, an estimated $131M added.
- The largest BioNTech seller in Q1 2023 was T. Rowe Price Associates, an estimated $99.3M sold.
Based on aggregated 13F filings for Q1 2023.